Renowned molecular geneticist and Harvard Professor, George Church will speak at the Next Generation Dx Summit to take place in Washington, DC on August 24-26. Dr. Church will discuss how the evolution of next generation sequencing technology is significantly enhancing the diagnostic landscape for infectious disease, and will offer a perspective on the need to demonstrate clear clinical benefits to achieve more wide spread adoption by healthcare organizations and clinicians.
Church, who recently co-founded Pathogenica ™ with Adeyemi Adesokan, will use Pathogenica as a study in how next generation technologies such as his company's unique BioDetection (DxSeq) system are significantly faster and more affordable than the current standards, thereby facilitating more widespread adoption by healthcare providers.
Pathogenica's novel BioDetection ™ system utilizes next-generation DNA sequencing technology to provide high throughput, ultra-low cost assays with high sensitivity and specificity for rapid multiplex identification of pathogens, such as MRSA and human viruses. This unique multiplexing technology can target many pathogens simultaneously, greatly accelerating accurate diagnosis from the current 4-10 days by culture, to under 24 hours, and all at less than a dollar per pathogen. Low cost multiplexed diagnostic assays offer a convincing solution to questions over current healthcare reimbursement for nucleic acid tests, and can save millions of dollars of unnecessary single pathogen assays.
In his presentation, Church will outline Pathogenica's strategy toward Clinical Laboratory Improvement Amendments (CLIA) certification and FDA-approved diagnostic panels, present proof of concept application of Pathogenica's technology for detection of multiple pathogens in clinical samples, and discuss new approaches to diagnostic monitoring enabled by this low-cost technology.
Source: Pathogenica
Комментариев нет:
Отправить комментарий